CD8A and neoplasm: As compared with the vaccination of RFP only, the genetically engineered hFTN (i.e. hFTN-RFP) that densely presents RFPs on the hFTN surface effectively targeted LNs and stayed in the LNs for a sufficiently long period of time, significantly increased the T cell population in LNs, induced strong and antigen-specific CD8+ T cell response, and successfully inhibited the RFP-expressing tumor growth based on its antigen-specific anti-tumor activity.